Summary
Background Epidermolysis bullosa acquisita (EBA) is a complex autoimmune bullous disease disease with variable clinical presentations and multiple possible diagnostic tests, making an international consensus on the diagnosis of EBA essential.
Objectives To obtain an international consensus on the clinical and diagnostic criteria for EBA. Methods The International Bullous Diseases Group (IBDG) met three times to discuss the clinical and diagnostic criteria for EBA. For the final voting exercise, 22 experts from 14 different countries voted on 50 different items. When > 30% disagreed with a proposal, a discussion was held and re-voting carried out. Results In total, 48 of 50 proposals achieved consensus after discussion. This included nine diagnostic criteria, which are summarized in a flow chart. The IBDG was unable to determine one procedure that would be applicable worldwide. A limitation of the study is that differential diagnosis of bullous systemic lupus erythematosus has not been addressed. Conclusions This first international consensus conference established generally agreed-upon clinical and laboratory criteria defining the clinical classification of and diagnostic testing for EBA. Holding these voting exercises in person with the possibility of discussion prior to voting has advantages in reaching consensus over Delphi exercises with remote voting.
• These recommendations, which have been developed by international experts, provide appropriate pathways for EBA diagnosis: the algorithms may be used to distinguish EBA from other blistering diseases, which affect the epithelial basement membrane zone.
The International Bullous Diseases Group (IBDG) was formed in 2005 following a research meeting at the National Institutes of Health for experts in blistering diseases to work towards a consensus for the development and validation of definitions and outcome measures in autoimmune bullous diseases (AIBDs). 1 The IBDG focused its efforts initially on pemphigus, with consensus definitions, development and validation of the Pemphigus Disease Area Index and the Autoimmune Bullous Skin Intensity Score. 1, 2 Subsequently, the IBDG published consensus definitions for bullous pemphigoid (BP) and proposed the BP Disease Area Index severity tool, 3 and then consensus definitions for mucous membrane (MM) pemphigoid (MMP) and the MMP Disease Area Index. 4 The current project relates to international consensus definitions on diagnostic criteria for epidermolysis bullosa acquisita (EBA). Two cases of an adult-onset, acquired blistering disease that was reminiscent of patients with hereditary dystrophic epidermolysis bullosa (EB) were reported in 1895 by Elliott. 5 A landmark paper on the subject was published in 1971 by Roenigk et al., who described three new cases of EBA, reviewed the world literature and proposed the first diagnostic criteria for EBA. 6 These criteria were soon modified by the advent of immunofluorescence (IF) and the finding that all patients with EBA had IgG and sometimes C3 deposits in their dermoepidermal junction (DEJ) and that by immunoelectron microscopy (IEM), these DEJ immune deposits were clearly in a different location than immune deposits observed in BP. [7] [8] [9] [10] The IgG autoantibodies (autoAbs) accounting for these DEJ immune deposits were found to be autoAbs directed against a 290-kDa protein called type VII collagen (Col7), the major component of anchoring fibrils (AFs) in the DEJ. 11, 12 Since these initial observations, the diagnostic testing for EBA has undergone significant refinement.
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Methods
The IBDG met three times during 2015: at the annual meetings of the American Academy of Dermatology in San Francisco (21 experts from 11 countries); the European Society of Dermatological Research in Rotterdam (11 experts from six countries); and the European Academy of Dermatology and Venereology (EADV) in Copenhagen (22 experts from 14 countries). Initial presentations and discussions took place at the first two meetings. After further revisions and discussions at the third meeting, consensus voting took place on the definitions and diagnostic techniques. We defined 'consensus' according to Harmonize Outcome Measures for Eczema by having less than one-third of the key opinion leaders disagreeing on a given diagnostic criterion. 16, 17 Fifty proposals (Table S1 ; see Supporting Information) were put forward for discussion and voting related to the diagnostic processes involved in EBA. For each proposal, participants could 'agree', be 'undecided' or 'disagree'. Tables summarizing the literature  (Tables S2-S6; see Supporting Information) and examples of cases of EBA (Appendix S2; see Supporting Information) were presented for discussion.
Results
Altogether, 38 experts in EBA from 15 countries took part in this consensus, although not all were able to attend all three international meetings held in San Francisco, Rotterdam and Copenhagen. The actual results of the voting questions (Table S7 ; see Supporting Information) and the reported anonymized results in the final version of the approved wording or procedures were from 22 blistering disease experts from 14 different countries ( Fig. S1 ; see Supporting Information). Although not all members of the IBDG were present at the final voting meeting, all co-authors were in agreement with the EBA diagnostic criteria detailed herein.
Definition and clinical variants of epidermolysis bullosa acquisita
EBA is defined as a subepithelial AIBD in which patients have tissue-bound autoAbs targeted against Col7 within AFs of the basement membrane zone (BMZ) of the DEJ or chorioepithelial junction (CEJ) in stratified squamous epithelia. Several forms of EBA exist, with two major types, termed: (i) the classical/mechanobullous form; and (ii) the nonclassical/nonmechanobullous forms, first described by Gammon et al. in 1982 . 18 The latter includes forms that may clinically resemble BP, MMP, Brunsting-Perry pemphigoid and linear IgA bullous dermatosis. 6, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Table 1 and Figure 1 summarize the descriptions and definitions of these four phenotypes.
The frequency of these subtypes varies in different countries, with the classical type being the most common in European reports and the BP-like form more common in Asia (Table S2) . [36] [37] [38] [39] 40 the diagnostic possibility that the patient has EBA, rather than BP, rises considerably. Finally, it is important to classify cases of MM-predominant EBA (MM-EBA) because the severity of mucosal involvement dictates more aggressive, multidisciplinary management. There has been confusion in the literature as to which forms constitute an 'inflammatory' form of EBA. 13, 20, 22, 23, [36] [37] [38] [39] The IBDG members agreed that the BP-like form is inflammatory but that both MM-EBA and IgA-EBA may also be inflammatory. However, Brunsting-Perry-like EBA is usually a noninflammatory form of EBA.
Laboratory testing for epidermolysis bullosa acquisita
The IBDG reached agreement on the following proposal: routine histopathology, direct IF (DIF) microscopy and indirect IF (IIF) -which are widely available laboratory tests -allow a diagnosis of subepithelial AIBD but are not able to distinguish EBA from another subepidermal AIBD. Routine histopathology on a biopsy obtained from lesional skin or MM of a patient with EBA shows (i) subepidermal or subepithelial cleavage; (ii) great variability in the amount or type of inflammatory infiltrate; and (iii) milia cysts and fibrosis in older lesions. Routine DIF microscopy of perilesional skin or MM shows (i) linear immune deposits along the BMZ of the DEJ or CEJ, and (ii) no labelling of dermal blood vessels. The profile of immune deposits includes IgG and C3 but occasionally IgA or IgM (Table S3 , case report 5; see Supporting Information). [41] [42] [43] Routine IIF microscopy on monkey, rat or rabbit oesophagus or human skin can detect anti-BMZ autoAbs, but it is often at a low titre. Currently, a diagnosis of EBA should be confirmed by at least one of the following tests, which are only performed in academic centres and are not widely available to the average dermatologist worldwide: 13 44 Obviously, all these serological tests require that the patient with EBA has autoAbs to Col7 circulating in their blood and it must be kept in mind that anti-Col7 autoAbs are also present in bullous systemic lupus erythematosus (BSLE). 53 Alternative laboratory tests when none of these tests is available include DIF and IIF on salt-split skin (SSS), 54 but they will not absolutely confirm the diagnosis of EBA.
55,56
Standard transmission electron microscopy and immunoelectron microscopy
In patients with EBA, standard transmission EM shows an electron-dense band immediately below the lamina densa (LD) in the AF zone. Another EM finding suggestive of EBA is that the cleavage occurs below the LD, which remains attached to the roof of the blister. A paucity of AFs also supports a diagnosis of EBA.
44 • with features characteristic of BP (pruritus, tense bullae on erythematous or urticarial skin, involvement of trunk and folds)
• usually mixed with atypical lesions for a BP (skin fragility, bullae on normal skin, milia, involvement of face or extensor area of the limbs)
MM-EBA, defined as a disease that predominantly affects MM lined by squamous epithelium, i.e. MM of: [20] [21] [22] [23] [24] [25] [26] [27] • mouth
Brunsting-Perry-type EBA, defined as a chronic recurrent blistering dermatosis confined to the head and neck [28] [29] [30] [31] [32] IgA-EBA, defined as a disease that presents with linear IgA deposits in the BMZ that can be observed by direct IF: 20, 33, 34 • it may resemble LABD • it may be more aggressive with mucosal scarring Direct IEM on perilesional skin shows in vivo bound immune deposits that are very thick and located in the AF zone, and a cleavage under immune deposits, if EBA is present (Fig. 2) . 44 The IBDG agreed on the limitations of direct IEM (proposal 29). Sixteen members of the consensus group attending the EADV round of voting had EM available at their site, but only about half of the group had experience in using EM and only seven were currently using IEM.
Serration pattern analysis
DIF microscopy of a perilesional skin biopsy can distinguish EBA from other subepithelial AIBD by showing a 'u-serrated' linear pattern of immunoglobulin deposits along the BMZ in EBA and BSLE, and an 'n-serrated' pattern of immunoglobulin deposits in BP, antilaminin 332 MMP and anti-p200/ laminin c1 pemphigoid (Fig. 3) . 41, 45, 46, 55, 56 No agreement was obtained on limitations of the serration pattern analysis (proposal 26). Indeed, it can be performed with routine DIF microscopy (new, unpublished data on the exact requirements can be read in Supplementary Data S2 of Appendix S2). However, to date, this test is not widely available and so far only the teams in Groningen and L€ ubeck have been able to master the technique (proposal 26bis).
Fluorescent overlay antigen mapping analysis
In EBA, FOAM, using routine IF microscopy with either an image analysis system or laser scanning confocal microscopy, [47] [48] [49] shows in vivo bound immune deposits below the basal keratinocyte membrane, lamina lucida and LD components (Fig. 4) .
Enzyme-linked immunosorbent assay
Commercially available ELISAs using recombinant NC1/noncollagenous 2 (NC2) Col7, [57] [58] [59] [60] or NC1 Col7, 50 are widely available. Sensitivities vary depending on the selection criteria. It is very high (79-96Á7%) on preselected positive sera by IIF on SSS, with floor labelling (Table S4 ; see Supporting Information). The sensitivity of ELISA to NC1/NC2 is lower (30-54%) in studies on unselected EBA sera.
39,61
An ELISA using full-length Col7 is more sensitive than an ELISA using NC1/NC2 Col7 but is not commercially available (Table S5; see Supporting Information) . 39, 42, 62, 63 ELISAs for Col7 are not highly specific as they may be positive in patients with Crohn disease or ulcerative colitis without cutaneous manifestations of EBA, 64 atypical AIBD 65 and patients with recessive dystrophic EB (RDEB) ( Tables S5 and  S6) . 39, 63, 66, 67 Of note, the presence of circulating autoAbs against BP180, laminin 332 and the p200/laminin c1 chain (detected by IB or ELISA), which may occur as a result of the epitope spreading phenomenon, does not rule out a diagnosis of EBA (supplementary cases 2 and 4 in Appendix S2).
37,68-75
Novel technique: indirect immunofluorescence using noncollagenous 1 type VII collagen-transfected cells
Patient serum autoAbs could label NC1 Col7-transfected cells on a special slide, a so-called BIOCHIP TM method (Fig. 5 ). This test is now commercially available and could be used as a substitute for the ELISA outlined above. It is a sensitive, specific and rapid assay for testing preselected positive sera by IIF on SSS with floor labelling. 50 Like serological testing by ELISA, its sensitivity is lower in studies on unselected EBA sera. 
Immunoblotting
IB is a serological technique performed on extracts of tissues or cells or recombinant Col7 proteins (Fig. 6) . 13, 15, 35 IB is effective for diagnosing EBA by detecting autoAbs in patient sera that label the Col7 a-chain. IB can substitute for the commercially available ELISA. The IBDG agreed on the limitations of IB (proposal 33).
Indirect immunofluorescence on type VII collagen-deficient human skin and indirect immunoelectron microscopy
A definitive diagnosis of EBA can be demonstrated by IIF when presumptive EBA sera label the DEJ of normal human skin but do not label skin from generalized severe RDEB with no Col7 (Fig. 7) . 51, 52 Obviously, this is not offered in commercial laboratories and is limited by access to skin specimens from patients with this exceedingly rare disease. A definitive diagnosis of EBA can also be demonstrated when presumptive EBA sera label AFs by indirect IEM (Fig. 2) . 44 Direct and indirect immunofluorescence microscopy on salt-split skin DIF and IIF on SSS are alternative laboratory tests that only give a probable diagnosis of EBA. DIF is performed after splitting the skin biopsy of the patient using NaCl 1 mol L
À1
(Supplementary Data S3 in Appendix S2). 54, 76 It is not possible with MM biopsies. IIF may be performed on either normal human SSS using a similar procedure, 19, [77] [78] [79] or monkey SSS, which is commercially available. Immune deposits in patients with EBA remain on the dermal floor of the separation, whereas BP immune deposits remain with the epidermal roof ( Fig. 8) . However, this dermal labelling is not specific to EBA. It is also seen in antilaminin 332 MMP and anti 1-p200/ laminin c1 pemphigoid (Fig. 4) . Additional tests are necessary to exclude reactivity against these molecules and finally diagnose EBA. Overall, IIF on SSS is more sensitive than IIF on monkey or rat oesophagus or unsplit human skin for detecting anti-BMZ autoAbs. 77, 79 Lastly, the IBDG updated consensus criteria for EBA diagnosis (2015) include combinations of the following tests: (1) a bullous disorder within the defined clinical spectrum; (2) histopathology revealing a subepidermal or subepithelial blister; (3) a positive DIF microscopy of perilesional skin or MM with linear IgG, C3, IgA and/or IgM deposits within the epithelial BMZ; (4) detection of circulating autoAbs against Col7 by IB, ELISA and/or IIF microscopy on Col7-expressing human cells; (5) labelling AFs by indirect IEM or negative IIF microscopy on Col7-deficient skin; (6) a 'u-serration' pattern by DIF microscopy; (7) direct IEM of perilesional skin demonstrating immune deposits within AFs zone AE the lower LD; (8) in vivo bound immune deposits below type IV collagen by FOAM; (9) alternatively to items (4)- (8), dermal labelling by DIF and/or IIF on SSS.
The IBDG did reach agreement that the ideal scenario is for a patient with putative EBA disease (criterium 1) to exhibit a subepidermal bulla by histology (criterium 2 optional), a positive DIF microscopy (criterium 3) and an ELISA (or another serological test) showing that the patient's serum autoAbs target Col7 [criterium (4) or (5)]. In this scenario, a highly probable diagnosis of EBA is made and no further tests need to be done for confirmation. Unlike this ideal scenario for the diagnosis of EBA, the problem that often arises is when a patient with EBA lacks circulating autoAbs and therefore IIF, SSS IIF and ELISA are negative. 39, 61 Then the diagnosis of EBA could be considered definitive if criteria (1) and (3) and at least one of criteria (6)- (8) [criterium (2) is optional]. Lastly, if tests (6)- (8) cannot be done, a diagnosis of EBA is possible if items criteria (1), (3) and (9) are present; then diagnosis has to be confirmed by exclusion of autoimmunity against laminin 332 or the p200/laminin c1 chain. The consensus conference was not able to determine one procedure that would be applicable worldwide. There was an animated discussion about what should be considered routine (Proposal 18). Which test(s) that the practitioner chooses will likely be determined by the clinical presentation of the patient (classical/mechanobullous type or not), the geography of the practitioner and which test is most logistically accessible. Figure 9 summarizes the different diagnostic investigative pathways.
In conclusion, this consensus of the criteria for the diagnosis of EBA provides a general framework for establishing a diagnosis of EBA and takes into account the clinical presentation and available laboratory testing. These criteria should help prevent clinicians from misdiagnosing other AIBDs and missing the diagnosis of EBA. They will also be useful for future studies designed to define the natural history and therapeutic outcomes of EBA. Flow chart for diagnosis of epidermolysis bullosa acquisita (EBA). Type VII collagen (Col7)-specific enzyme-linked immunosorbent assays (ELISAs) include noncollagenous (NC)1, NC1/NC2 or full-length Col7 ELISAs. BIOCHIP TM technology uses NC1 Col7-transfected human embryonic kidney (HEK)293 cells as a substrate for indirect immunofluorescence (IIF) microscopy (IIFT test). Col7-deficient skin is obtained from patients with generalized severe recessive dystrophic epidermolysis bullosa. DIF, direct immunofluorescence; DEJ, dermoepidermal junction; CEJ, chorioepithelial junction; AIBD, autoimmune blistering disease; autoAb, autoantibody; Col7, type VII collagen; WB, Western blotting; MM, mucous membranes; IEM, immunoelectron microscopy; FOAM, fluorescence overlay antigen mapping; Col4, type IV collagen; LL, lamina lucida; LD, lamina densa; BP, bullous pemphigoid; MMP, mucous membrane pemphigoid; SSS, salt-split skin (artificial cleavage obtained by incubation of normal monkey or human skin with NaCl 1 mol L À1 ). a NC1 ELISA, NC1/NC2 ELISA, NC1 Col7-transfected HEK293 cells and monkey SSS are commercially available; b negativity on Col7-deficient skin is significant if IIF microscopy on normal human skin is positive; c include WB with dermal extract or recombinant C-terminus laminin c1 or IIF on laminin 332-deficient skin.
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